First Header Logo Second Header Logo

Connection

Douglas Lyles to Animals

This is a "connection" page, showing publications Douglas Lyles has written about Animals.
Connection Strength

1.020
  1. Yu N, Puckett S, Antinozzi PA, Cramer SD, Lyles DS. Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol. 2015 May; 89(10):5250-63.
    View in: PubMed
    Score: 0.056
  2. Smedberg JR, Westcott MM, Ahmed M, Lyles DS. Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin. J Virol. 2014 Jan; 88(2):777-85.
    View in: PubMed
    Score: 0.051
  3. Westcott MM, Ahmed M, Smedberg JR, Rajani KR, Hiltbold EM, Lyles DS. Preservation of dendritic cell function during vesicular stomatitis virus infection reflects both intrinsic and acquired mechanisms of resistance to suppression of host gene expression by viral M protein. J Virol. 2013 Nov; 87(21):11730-40.
    View in: PubMed
    Score: 0.051
  4. Stewart JH, Ahmed M, Northrup SA, Willingham M, Lyles DS. Vesicular stomatitis virus as a treatment for colorectal cancer. Cancer Gene Ther. 2011 Dec; 18(12):837-49.
    View in: PubMed
    Score: 0.044
  5. Gerlier D, Lyles DS. Interplay between innate immunity and negative-strand RNA viruses: towards a rational model. Microbiol Mol Biol Rev. 2011 Sep; 75(3):468-90, second page of table of contents.
    View in: PubMed
    Score: 0.044
  6. Cary ZD, Willingham MC, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol. 2011 Jun; 85(12):5708-17.
    View in: PubMed
    Score: 0.043
  7. Ahmed M, Puckett S, Arimilli S, Braxton CL, Mizel SB, Lyles DS. Stimulation of human dendritic cells by wild-type and M protein mutant vesicular stomatitis viruses engineered to express bacterial flagellin. J Virol. 2010 Nov; 84(22):12093-8.
    View in: PubMed
    Score: 0.041
  8. Braxton CL, Puckett SH, Mizel SB, Lyles DS. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens. J Virol. 2010 Apr; 84(7):3552-61.
    View in: PubMed
    Score: 0.039
  9. Dancho B, McKenzie MO, Connor JH, Lyles DS. Vesicular stomatitis virus matrix protein mutations that affect association with host membranes and viral nucleocapsids. J Biol Chem. 2009 Feb 13; 284(7):4500-9.
    View in: PubMed
    Score: 0.037
  10. Carey BL, Ahmed M, Puckett S, Lyles DS. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol. 2008 Dec; 82(24):12104-15.
    View in: PubMed
    Score: 0.036
  11. Ahmed M, Marino TR, Puckett S, Kock ND, Lyles DS. Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J Virol. 2008 Sep; 82(18):9273-7.
    View in: PubMed
    Score: 0.035
  12. Swinteck BD, Lyles DS. Plasma membrane microdomains containing vesicular stomatitis virus M protein are separate from microdomains containing G protein and nucleocapsids. J Virol. 2008 Jun; 82(11):5536-47.
    View in: PubMed
    Score: 0.035
  13. Connor JH, McKenzie MO, Parks GD, Lyles DS. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology. 2007 May 25; 362(1):109-19.
    View in: PubMed
    Score: 0.032
  14. Gaddy DF, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol. 2007 Mar; 81(6):2792-804.
    View in: PubMed
    Score: 0.032
  15. Connor JH, McKenzie MO, Lyles DS. Role of residues 121 to 124 of vesicular stomatitis virus matrix protein in virus assembly and virus-host interaction. J Virol. 2006 Apr; 80(8):3701-11.
    View in: PubMed
    Score: 0.030
  16. Brown EL, Lyles DS. Pseudotypes of vesicular stomatitis virus with CD4 formed by clustering of membrane microdomains during budding. J Virol. 2005 Jun; 79(11):7077-86.
    View in: PubMed
    Score: 0.029
  17. Gaddy DF, Lyles DS. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol. 2005 Apr; 79(7):4170-9.
    View in: PubMed
    Score: 0.028
  18. Connor JH, Lyles DS. Inhibition of host and viral translation during vesicular stomatitis virus infection. eIF2 is responsible for the inhibition of viral but not host translation. J Biol Chem. 2005 Apr 08; 280(14):13512-9.
    View in: PubMed
    Score: 0.028
  19. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology. 2004 Dec 05; 330(1):34-49.
    View in: PubMed
    Score: 0.028
  20. Connor JH, Naczki C, Koumenis C, Lyles DS. Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol. 2004 Sep; 78(17):8960-70.
    View in: PubMed
    Score: 0.027
  21. Brown EL, Lyles DS. A novel method for analysis of membrane microdomains: vesicular stomatitis virus glycoprotein microdomains change in size during infection, and those outside of budding sites resemble sites of virus budding. Virology. 2003 Jun 05; 310(2):343-58.
    View in: PubMed
    Score: 0.025
  22. Brown EL, Lyles DS. Organization of the vesicular stomatitis virus glycoprotein into membrane microdomains occurs independently of intracellular viral components. J Virol. 2003 Apr; 77(7):3985-92.
    View in: PubMed
    Score: 0.025
  23. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol. 2003 Apr; 77(8):4646-57.
    View in: PubMed
    Score: 0.025
  24. Kopecky SA, Lyles DS. Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol. 2003 Apr; 77(8):4658-69.
    View in: PubMed
    Score: 0.025
  25. Ahmed M, Lyles DS. Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III. J Virol. 1998 Oct; 72(10):8413-9.
    View in: PubMed
    Score: 0.018
  26. Lyles DS, McKenzie MO. Activity of vesicular stomatitis virus M protein mutants in cell rounding is correlated with the ability to inhibit host gene expression and is not correlated with virus assembly function. Virology. 1997 Mar 03; 229(1):77-89.
    View in: PubMed
    Score: 0.016
  27. Lyles DS, McKenzie MO, Ahmed M, Woolwine SC. Potency of wild-type and temperature-sensitive vesicular stomatitis virus matrix protein in the inhibition of host-directed gene expression. Virology. 1996 Nov 01; 225(1):172-80.
    View in: PubMed
    Score: 0.016
  28. Lyles DS, McKenzie MO, Hantgan RR. Stopped-flow, classical, and dynamic light scattering analysis of matrix protein binding to nucleocapsids of vesicular stomatitis virus. Biochemistry. 1996 May 21; 35(20):6508-18.
    View in: PubMed
    Score: 0.015
  29. Lyles DS, McKenzie MO, Kaptur PE, Grant KW, Jerome WG. Complementation of M gene mutants of vesicular stomatitis virus by plasmid-derived M protein converts spherical extracellular particles into native bullet shapes. Virology. 1996 Mar 01; 217(1):76-87.
    View in: PubMed
    Score: 0.015
  30. Blackham AU, Northrup SA, Willingham M, Sirintrapun J, Russell GB, Lyles DS, Stewart JH. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma. J Surg Res. 2014 Apr; 187(2):412-26.
    View in: PubMed
    Score: 0.013
  31. Randle RW, Northrup SA, Sirintrapun SJ, Lyles DS, Stewart JH. Oncolytic vesicular stomatitis virus as a treatment for neuroendocrine tumors. Surgery. 2013 Dec; 154(6):1323-29; discussion 1329-30.
    View in: PubMed
    Score: 0.013
  32. Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ. Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses. PLoS One. 2013; 8(6):e67123.
    View in: PubMed
    Score: 0.012
  33. Blackham AU, Northrup SA, Willingham M, D'Agostino RB, Lyles DS, Stewart JH. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus. Surgery. 2013 Mar; 153(3):333-43.
    View in: PubMed
    Score: 0.012
  34. Johnson JB, Lyles DS, Alexander-Miller MA, Parks GD. Virion-associated complement regulator CD55 is more potent than CD46 in mediating resistance of mumps virus and vesicular stomatitis virus to neutralization. J Virol. 2012 Sep; 86(18):9929-40.
    View in: PubMed
    Score: 0.012
  35. Agnihothram SS, Dancho B, Grant KW, Grimes ML, Lyles DS, Nunberg JH. Assembly of arenavirus envelope glycoprotein GPC in detergent-soluble membrane microdomains. J Virol. 2009 Oct; 83(19):9890-900.
    View in: PubMed
    Score: 0.010
  36. Ahmed M, Mitchell LM, Puckett S, Brzoza-Lewis KL, Lyles DS, Hiltbold EM. Vesicular stomatitis virus M protein mutant stimulates maturation of Toll-like receptor 7 (TLR7)-positive dendritic cells through TLR-dependent and -independent mechanisms. J Virol. 2009 Apr; 83(7):2962-75.
    View in: PubMed
    Score: 0.009
  37. Trottier MD, Lyles DS, Reiss CS. Peripheral, but not central nervous system, type I interferon expression in mice in response to intranasal vesicular stomatitis virus infection. J Neurovirol. 2007 Oct; 13(5):433-45.
    View in: PubMed
    Score: 0.008
  38. Hantgan RR, Stahle MC, Connor JH, Lyles DS, Horita DA, Rocco M, Nagaswami C, Weisel JW, McLane MA. The disintegrin echistatin stabilizes integrin alphaIIbbeta3's open conformation and promotes its oligomerization. J Mol Biol. 2004 Oct 01; 342(5):1625-36.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.